0001209191-20-054346.txt : 20201008
0001209191-20-054346.hdr.sgml : 20201008
20201008191021
ACCESSION NUMBER: 0001209191-20-054346
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20201008
FILED AS OF DATE: 20201008
DATE AS OF CHANGE: 20201008
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Loven Jakob
CENTRAL INDEX KEY: 0001753644
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39592
FILM NUMBER: 201231818
MAIL ADDRESS:
STREET 1: C/O ARVINAS, INC., 5 SCIENCE PARK
STREET 2: 395 WINCHESTER AVENUE
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kronos Bio, Inc.
CENTRAL INDEX KEY: 0001741830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
BUSINESS PHONE: 212-871-7920
MAIL ADDRESS:
STREET 1: 1300 S. EL CAMINO REAL
STREET 2: SUITE 300
CITY: SAN MATEO
STATE: CA
ZIP: 94402
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-10-08
0
0001741830
Kronos Bio, Inc.
KRON
0001753644
Loven Jakob
C/O KRONOS BIO, INC.
1300 SO. EL CAMINO REAL, SUITE 300
SAN MATEO
CA
94402
1
0
0
0
Series A Preferred Stock
Common Stock
1376313
I
See footnote
Convertible Promissory Note
16.15
2022-02-20
Common
169031
I
See footnote
Each share of Series A Preferred Stock (the "Preferred Stock") is convertible into 1.055 shares of Common Stock. The Preferred Stock has no expiration date.
Represents shares of common stock issuable upon conversion of preferred stock held by Nextech V Oncology S.C.S, SICA-SIF ("Nextech V"). The reporting person currently serves as a member of the leadership team at Nextech Invest AG ("Nextech AG"), the investment advisor to Nextech V, and may be deemed to have shared voting and/or investment power over the securities held by Nextech V. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The convertible promissory note will automatically convert into shares of the Issuer's common stock upon the closing of the Issuer's first firm commitment underwritten initial public offering.
/s/ David Tanen, Attorney-in-fact
2020-10-08
EX-24.3_940990
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and appoints
each of David Tanen, Yasir Al-Wakeel, Barbara Kosacz and Allison Frisbee of
Kronos Bio, Inc. (the "Company"), signing individually, the undersigned's true
and lawful attorney-in fact and agent to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of the Company, Forms 3, 4
and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, is not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorney-in-fact or (c) until such attorney-in-fact
shall no longer be employed by the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 2nd day of October 2020.
/s/ Jakob Loven, Ph.D.